Arch Linux isn’t even close to the hardest distro out there—here’s what really is.

The attacker appears to have targeted FortiGate devices whose management ports were exposed online, used weak passwords, and lacked MFA.

DENVER, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Execution is the theme this morning, as a cluster of emerging growth names move from pilot programs and strategic roadmaps into operational scale. Kraig ...

Investment management company First Pacific Advisors recently released its “FPA Queens Road Small Cap Value Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The ...

Multi-year partnership will utilize Iambic’s broad suite of AI drug discovery technologies and wet lab capabilities to advance collaboration programs initially in Takeda’s Oncology and ...

Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery ...

Nicholas Ralph and Callum Woodhouse flip the script and play each other's roles in a scene. This time around, Nicholas Ralph plays Tristan and Callum Woodhouse plays James. Watch the actors flip the ...

Gaethje defeats Pimblett for interim UFC lightweight title Paramount's $7.7 billion deal with UFC begins Fighter pay concerns arise despite doubled bonuses Jan 25 (Reuters) - Justin Gaethje rolled ...

If the first few trading sessions of the year are any indication, 2026 is set to be the year of the small-cap trade. The Russell 2000 hit all-time closing and intraday highs Thursday, putting the ...

A newly discovered advanced cloud-native Linux malware framework named VoidLink focuses on cloud environments, providing attackers with custom loaders, implants, rootkits, and plugins designed for ...

Researchers have discovered a never-before-seen framework that infects Linux machines with a wide assortment of modules that are notable for the range of advanced capabilities they provide to ...

A small biopharma company said its experimental depression drug is moving into Phase 3 trials, sending its shares soaring about 35% in premarket trading on Monday. GH Research GHRS now plans to put ...